Benitec Biopharma Ltd (ASX:BLT; NASDAQ:BNTC) should gain a boost today as its Hepatitis B therapy has been seen to reduce the virus (HBV) by 98.5% in a mice study.
The in vivo study assessed the activity of BB-HB-331 treatment in the PhoenixBio (PXB) mouse model and demonstrated robust and durable suppression of HBV in vivo following a single administration.
Benitec's ddRNAi technology is a combination of gene silencing using RNA interference coupled with the long term therapeutic potential of gene therapy.
Once infected with HBV, mice were treated with a one time systemic injection of BB-HB-331. Weekly assessment of serum antigen levels, HBV viral proteins and extracellular HBV DNA were conducted for the duration of the 56 day study.
The key findings in this study were that a single BB-HB-331 treatment reduced serum HBV DNA by 1.83 logs, equivalent to 98.5% elimination of circulating HBV.
The in vivo experiment validates the BB-‐HB-331 in vitro findings previously observed in human hepatocytes isolated from the PXB mouse model which was announced on 7 December 2015.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.